Red cell distribution width (RDW), an automated measure of variability in red blood cell size on full blood count (FBC), has recently emerged as a strong independent predictor of mortality in large population studies as well as several disease states. We wanted to determine the prognostic value of RDW in patients following a hip fracture - a condition associated with high mortality. This relationship has not been assessed to date. We examined the relationship between admission RDW and all-cause mortality on 1-year follow-up, in consecutive hip fracture cases who presented between January 2007 and November 2009. We used Cox regression analysis to adjust for baseline Haemoglobin (Hb), Mean corpuscular Volume (MCV), creatinine, age, gender, ASA grade, Charlson index, pre-morbid independence level, Mental test score (MTS), delay to surgery and post-operative cardio-respiratory complication.Background
Methods
Surgery for pelvic or acetabular fractures carries a high risk of deep-vein thrombosis (DVT). Reports indicate that fondaparinux is a more effective thromboprophylactic agent than low molecular weight heparin (LMWH) after major orthopaedic surgery. We prospectively evaluated a new protocol for DVT prophylaxis using fondaparinux. One hundred and eight patients with pelvic or acetabular fractures were randomised to receive either fondaparinux or enoxaparin. Specific review points included the primary end-point of clinical deep vein thrombosis (DVT) or pulmonary embolism (PE) and any evidence of adverse effects such as bleeding or allergic reactions. Two patients that received enoxaparin were found to have a DVT (3%) and one patient died from a PE (1%). There was no documented DVT or PE in patients that received fondaparinux. The mean number of units of blood transfused was significantly higher in the enoxaparin group and this was significant post-operatively (p<0.05). The current study supports that post-operative fondaparinux, in patients with pelvic and acetabular fractures, is more effective and equally safe to enoxaparin.Patients and methods
Results
